{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:22:27Z","timestamp":1791660147716,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.035","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T23:09:15Z","timestamp":1659308955000},"page":"5223-5228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-8473","authenticated-orcid":false,"given":"Saiprasad","family":"Narsingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Munson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Drescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2022.07.035_b0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.035_b0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2022.07.035_b0015","unstructured":"Pinkbook | Pneumococcal | Epidemiology of Vaccine Preventable Diseases | CDC. Published March 29, 2019. Accessed May 29, 2019. https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/pneumo.html."},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.035_b0020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","volume":"18","author":"Troeger","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.035_b0025","unstructured":"Pinkbook | Pneumococcal | Epidemiology of Vaccine Preventable Diseases | CDC. Accessed January 8, 2017. https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/pneumo.html."},{"key":"10.1016\/j.vaccine.2022.07.035_b0030","unstructured":"Immunization and Infectious Diseases | Healthy People 2020. Accessed May 29, 2019. https:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/immunization-and-infectious-diseases\/objectives."},{"key":"10.1016\/j.vaccine.2022.07.035_b0035","unstructured":"Surveillance Manual | Pneumococcal | Vaccine Preventable Diseases | CDC. Published March 29, 2019. Accessed May 29, 2019. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt11-pneumo.html."},{"issue":"RR-11","key":"10.1016\/j.vaccine.2022.07.035_b0040","first-page":"1","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep"},{"key":"10.1016\/j.vaccine.2022.07.035_b0045","unstructured":"Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521-524."},{"issue":"37","key":"10.1016\/j.vaccine.2022.07.035_b0050","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.07.035_b0055","unstructured":"Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102\u20131106."},{"issue":"46","key":"10.1016\/j.vaccine.2022.07.035_b0060","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u226565 Years: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.07.035_b0065","unstructured":"Grading of Recommendations Assessment, Development and Evaluation (GRADE) for use of PCV13 among adults \u226565 years old. Accessed September 6, 2020. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/PCV13.html."},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.035_b0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"15","author":"Peterson","year":"2019","journal-title":"Hum Vaccines Immunother"},{"issue":"38","key":"10.1016\/j.vaccine.2022.07.035_b0075","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.035_b0080","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.035_b0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.07.035_b0090","unstructured":"Canada PHA of. Pneumococcal vaccine: Canadian Immunization Guide. aem. Published July 18, 2007. Accessed February 12, 2021. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-16-pneumococcal-vaccine.html#a9."},{"key":"10.1016\/j.vaccine.2022.07.035_b0095","unstructured":"Information for policy makers | RIVM. Accessed February 12, 2021. https:\/\/www.rivm.nl\/en\/pneumococci\/information-for-policy-makers."},{"key":"10.1016\/j.vaccine.2022.07.035_b0100","unstructured":"Pneumococcal polysaccharide vaccine: patient group direction template. GOV.UK. Accessed February 12, 2021. https:\/\/www.gov.uk\/government\/publications\/pneumococcal-polysaccharide-vaccine-ppv-patient-group-direction-pgd-template."},{"key":"10.1016\/j.vaccine.2022.07.035_b0105","series-title":"Recognizing the 75th Anniversary of the Establishment of the Veterans Administration","author":"Evans","year":"2005"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.035_b0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jclinepi.2003.12.008","article-title":"Time-dependent bias was common in survival analyses published in leading clinical journals","volume":"57","author":"van Walraven","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.035_b0115","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1681\/ASN.2013050464","article-title":"A Within-Patient Analysis for Time-Varying Risk Factors of CKD Progression","volume":"25","author":"Li","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.035_b0120","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1097\/CCM.0b013e3181b7fbbb","article-title":"Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies","volume":"37","author":"Shintani","year":"2009","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.035_b0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.vaccine.2022.07.035_b0130","unstructured":"Matanock A. Considerations for PCV13 use among adults \u226565 years old and a summary of the evidence to recommendations framework. National Center for Immunization and Respiratory Diseases (U.S.), ed. 2019;201902(010202). https:\/\/stacks.cdc.gov\/view\/cdc\/80462."},{"key":"10.1016\/j.vaccine.2022.07.035_b0135","doi-asserted-by":"crossref","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;(1):CD000422. doi: 10.1002\/14651858.CD000422.pub3.","DOI":"10.1002\/14651858.CD000422.pub3"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.035_b0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study","volume":"67","author":"Musher","year":"2013","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.035_b0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.035_b0150","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/infdis\/jit506","article-title":"Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged \u226550 years with community-acquired pneumonia","volume":"208","author":"Sherwin","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.035_b0155","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods","volume":"50","author":"Johansson","year":"2010","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.035_b0160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/civ1214","article-title":"Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia","volume":"62","author":"Gadsby","year":"2016","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.035_b0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-2040-y","article-title":"Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review","volume":"16","author":"Remschmidt","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.035_b0170","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/649839","article-title":"Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Older Adults","volume":"201","author":"Musher","year":"2010","journal-title":"J Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2022.07.035_b0175","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2022.07.035_b0180","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.07.035_b0185","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(07)70210-4","article-title":"Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?","volume":"7","author":"O\u2019Brien","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2022.07.035_b0190","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60\u201364 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.035_b0195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/erv.11.8","article-title":"Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines","volume":"10","author":"Poolman","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.07.035_b0200","unstructured":"Safety Information for Pneumococcal Vaccines | CDC. Published September 23, 2021. Accessed May 2, 2022. https:\/\/www.cdc.gov\/vaccinesafety\/vaccines\/pneumococcal-vaccine.html."},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.035_b0205","doi-asserted-by":"crossref","first-page":"e020857","DOI":"10.1136\/bmjopen-2017-020857","article-title":"Validation of discharge diagnosis codes to identify serious infections among middle age and older adults","volume":"8","author":"Wiese","year":"2018","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.035_b0210","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/oxfordjournals.aje.a009804","article-title":"Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies","volume":"149","author":"Guevara","year":"1999","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.035_b0215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/cir767","article-title":"Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed","volume":"54","author":"Hermos","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.035_b0220","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jinf.2005.11.006","article-title":"The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens","volume":"53","author":"Guti\u00e9rrez","year":"2006","journal-title":"J Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:25Z","timestamp":1759403725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22009227"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}